US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciae386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Hiwot Hiruy und 34 weiteren Autor:innen. Beteiligte Einrichtung: Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Adm…. Hauptthemen laut MEDLINE: Gonorrhea, Anti-Bacterial Agents, Drug Development. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, Center for Drug Evaluation and Research, US FDA.
Abstract (Originalsprache)
There is an unmet need for developing drugs for the treatment of gonorrhea due to rapidly evolving resistance of Neisseria gonorrhoeae against antimicrobial drugs used for empiric therapy, an increase in globally reported multidrug-resistant cases, and the limited available therapeutic options. Furthermore, few drugs are under development. Development of antimicrobials is hampered by challenges in clinical trial design, limitations of available diagnostics, changes in and varying standards of care, lack of robust animal models, and clinically relevant pharmacodynamic targets. On 23 April 2021, the US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institute of Allergy and Infectious Diseases of the National Institutes of Health co-sponsored a workshop with stakeholders from academia, industry, and regulatory agencies to discuss the challenges and strategies, including potential collaborations and incentives, to facilitate the development of drugs for the treatment of gonorrhea. This article provides a summary of that workshop.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
- Office of Infectious Diseases, Office of New Drugs, CDER, FDA, Silver Spring, Maryland, USA.
- Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA, Silver Spring, Maryland, USA.
- Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, CDER, FDA, Silver Spring, Maryland, USA.
- Division of STD Prevention, National Center for HIV/AIDs, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
- Division of STD Prevention, NCHHSTP, CDC, Atlanta, Georgia, USA.
Förderung
- World Health Organization
- Center for Drug Evaluation and Research
- US FDA
- CARB-X
- US Department of Health and Human Services
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority
- Wellcome Trust
Zitieren
APA
Hiruy, H., Bala, S., Byrne, J. M., Roche, K. G., Jang, S. H., Kim, P., Nambiar, S., Rubin, D., Yasinskaya, Y., Bachmann, L. H., Bernstein, K., Botgros, R., Cammarata, S., Chaves, R. L., Deal, C. D., Drusano, G. L., Duffy, E. M., Eakin, A. E., Gelone, S., …, & Farley, J. J. (2026). US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae386
Vancouver
Hiruy H, Bala S, Byrne JM, Roche KG, Jang SH, Kim P, et al. US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciae386
BibTeX
@article{Hiruy2026,
author = {Hiruy, Hiwot and Bala, Shukal and Byrne, James M and Roche, Kerian Grande and Jang, Seong H and Kim, Peter and Nambiar, Sumathi and Rubin, Dan and Yasinskaya, Yuliya and Bachmann, Laura H and Bernstein, Kyle and Botgros, Radu and Cammarata, Sue and Chaves, Ricardo L and Deal, Carolyn D and Drusano, George L and Duffy, Erin M and Eakin, Ann E and Gelone, Steve and Hiltke, Thomas and Hook, Edward W and Jerse, Ann E and McNeil, Candice J and Newman, Lori and O'Brien, Seamus and Perry, Caroline and Reno, Hilary E L and Romaguera, Raul A and Sato, Junko and Unemo, Magnus and Wi, Teodora E C and Workowski, Kimberly and O'May, Graeme A and Shukla, Sunita J and Farley, John J},
title = {US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary—Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciae386}
}
EUVIMED